{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:54:17Z","timestamp":1793976857415,"version":"4.8.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiac amyloidosis (CA) is due to extracellular myocardial deposition of misfolded proteins resulting in severe cardiac dysfunction and death. The precursors of amyloid fibrils, able of determining a relevant cardiac infiltration, are immunoglobulin-free light chains (AL amyloidosis) and transthyretin (TTR) (both wild and mutated types). The diagnosis of amyloidosis represents a challenge for the clinician given its rarity and its protean clinical presentation, thus an early diagnosis remains a cornerstone for the prognosis of these patients, also in light of the growing available treatments. There is great interest in identifying and applying biomarkers to help diagnose, inform prognosis, guide therapy, and serve as surrogate endpoints in these patients. In AL amyloidosis, biomarkers such as free light chains, natriuretic peptides and troponins are the most extensively studied and validated; they have proved useful in risk stratification, guiding treatment choice and monitoring hematological and organ response. A similar biomarker-based prognostic score is also proposed for ATTR amyloidosis, although studies are small and need to be validated for wild-type and mutant forms.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s11739-022-02958-2","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:03:16Z","timestamp":1648166596000},"page":"957-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0276-8331","authenticated-orcid":false,"given":"Federico","family":"Perfetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-134X","authenticated-orcid":false,"given":"Mattia","family":"Zampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-5049","authenticated-orcid":false,"given":"Carlo","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-3543","authenticated-orcid":false,"given":"Marco","family":"Allinovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-0732","authenticated-orcid":false,"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"2958_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11739-011-0647-y","volume":"8","author":"F Perfetto","year":"2013","unstructured":"Perfetto F, Cappelli F, Bergesio F, Ciuti G, Porciani MC et al (2013) Cardiac amyloidosis: the heart of the matter. Intern Emerg Med 8:191\u2013203","journal-title":"Intern Emerg Med"},{"issue":"8","key":"2958_CR2","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","volume":"108","author":"G Merlini","year":"2006","unstructured":"Merlini G, Stone MJ (2006) Dangerous small B-cell clones. Blood 108(8):2520\u20132530","journal-title":"Blood"},{"issue":"7","key":"2958_CR3","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s11739-020-02489-8","volume":"16","author":"F Perfetto","year":"2021","unstructured":"Perfetto F, Casagrande S, Barilaro A, Di Gioia M, Santi R, Allinovi M, Romoli S, Boschi A, Desideri I, Taborchi G, Ungar A, Cappelli F (2021) Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis. Intern Emerg Med 16(7):1927\u20131933. https:\/\/doi.org\/10.1007\/s11739-020-02489-8 (Epub 2020 Sep 14)","journal-title":"Intern Emerg Med"},{"issue":"3","key":"2958_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","volume":"94","author":"RA Kyle","year":"2019","unstructured":"Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, Rajkumar SV, Vachon CM, Dispenzieri A (2019) Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 94(3):465\u2013471. https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.041 (Epub 2019 Jan 31)","journal-title":"Mayo Clin Proc"},{"key":"2958_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.1898365","volume":"10","author":"M Zampieri","year":"2021","unstructured":"Zampieri M, Cappelli F, Allinovi M, Olivotto I, Antonioli E, Tassetti L, Zocchi C, Andrei V, Di Mario C, Nozzoli C, Curciarello G, Ciciani AM, Bergesio F, Vannucchi AM, Perfetto F (2021) Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. Amyloid 10:1\u20132. https:\/\/doi.org\/10.1080\/13506129.2021.1898365","journal-title":"Amyloid"},{"key":"2958_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB (2015) Evolving landscape in the management of transthyretin amyloidosis. Ann Med 47:625\u2013638. https:\/\/doi.org\/10.3109\/07853890.2015.1068949","journal-title":"Ann Med"},{"key":"2958_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s004390050199","volume":"98","author":"DR Jacobson","year":"1996","unstructured":"Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN (1996) Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 98:236\u2013238. https:\/\/doi.org\/10.1007\/s004390050199","journal-title":"Hum Genet"},{"key":"2958_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","volume":"372","author":"CC Quarta","year":"2015","unstructured":"Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD (2015) The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 372:21\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1404852","journal-title":"N Engl J Med"},{"issue":"4","key":"2958_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","volume":"27","author":"M Russo","year":"2020","unstructured":"Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, Cavallaro T, Chiappini MG, Gemelli C, Pradotto LG, Manganelli F, Leonardi L, My F, Sampaolo S, Briani C, Gentile L, Stancanelli C, Di Buduo E, Pacciolla P, Salvi F, Casagrande S, Bisogni G, Calabrese D, Vanoli F, Di Iorio G, Antonini G, Santoro L, Mauro A, Grandis M, Di Girolamo M, Fabrizi GM, Pareyson D, Sabatelli M, Perfetto F, Rapezzi C, Merlini G, Mazzeo A, Vita G (2020) ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid 27(4):259\u2013265. https:\/\/doi.org\/10.1080\/13506129.2020.1794807 (Epub 2020 Jul 22)","journal-title":"Amyloid"},{"issue":"10","key":"2958_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/ejhf.1285","volume":"20","author":"C Gagliardi","year":"2018","unstructured":"Gagliardi C, Perfetto F, Lorenzini M et al (2018) Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. Eur J Heart Fail 20(10):1417\u20131425","journal-title":"Eur J Heart Fail"},{"key":"2958_CR11","doi-asserted-by":"publisher","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","volume":"2","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Whelan CJ, Petrie A et al (2013) Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2:e000098","journal-title":"J Am Heart Assoc"},{"key":"2958_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Non biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"2958_CR13","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585\u20132594","journal-title":"Eur Heart J"},{"key":"2958_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","volume":"270","author":"L Mohamed-Salem","year":"2018","unstructured":"Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J et al (2018) Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol 270:192\u2013196","journal-title":"Int J Cardiol"},{"issue":"4","key":"2958_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A (2021) Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 23(4):512\u2013526. https:\/\/doi.org\/10.1002\/ejhf.2140 (Epub 2021 Apr 7)","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2958_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-021-00483-7","volume":"11","author":"M Hasib Sidiqi","year":"2021","unstructured":"Hasib Sidiqi M, Gertz MA (2021) Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J 11(5):90. https:\/\/doi.org\/10.1038\/s41408-021-00483-7","journal-title":"Blood Cancer J"},{"issue":"11","key":"2958_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","volume":"27","author":"MIFJ Oerlemans","year":"2019","unstructured":"Oerlemans MIFJ, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N (2019) Cardiac amyloidosis: the need for early diagnosis. Neth Heart J 27(11):525\u2013536. https:\/\/doi.org\/10.1007\/s12471-019-1299-1","journal-title":"Neth Heart J"},{"key":"2958_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.04.021","author":"C Fumagalli","year":"2021","unstructured":"Fumagalli C, Zampieri M, Perfetto F, Zocchi C, Maurizi M (2021) Tassetti L et al Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis. Mayo Clin Proc. https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.021","journal-title":"Mayo Clin Proc"},{"key":"2958_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","volume":"82","author":"A Porcari","year":"2020","unstructured":"Porcari A, Merlo M, Rapezzi C, Sinagra G (2020) Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J Intern Med 82:7\u201315. https:\/\/doi.org\/10.1016\/j.ejim.2020.09.025 (Epub 2020 Oct 5)","journal-title":"Eur J Intern Med"},{"key":"2958_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejim.2020.08.012","volume":"82","author":"A Terr\u00e9","year":"2020","unstructured":"Terr\u00e9 A, Deshayes S, Savey L, Grateau G, Georgin-Lavialle S (2020) Cause of death and risk factors for mortality in AA amyloidosis: a French retrospective study. Eur J Intern Med 82:130\u2013132. https:\/\/doi.org\/10.1016\/j.ejim.2020.08.012 (Epub 2020 Aug 14)","journal-title":"Eur J Intern Med"},{"key":"2958_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood.V77.2.257.257","volume":"77","author":"MA Gertz","year":"1991","unstructured":"Gertz MA, Kyle RA, Greipp PR (1991) Response rates and survival in primary systemic amyloidosis. Blood 77:257\u2013262","journal-title":"Blood"},{"key":"2958_CR22","first-page":"45","volume":"32","author":"RA Kyle","year":"1995","unstructured":"Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45\u201359","journal-title":"Semin Hematol"},{"key":"2958_CR23","first-page":"105","volume":"30","author":"JA Katzmann","year":"2009","unstructured":"Katzmann JA (2009) Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 30:105\u2013111","journal-title":"Clin Biochem Rev"},{"key":"2958_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","volume":"55","author":"G Palladini","year":"2009","unstructured":"Palladini G, Russo P, Bosoni T, Verga L, Sarais G et al (2009) Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55:499\u2013504","journal-title":"Clin Chem"},{"key":"2958_CR25","first-page":"1734","volume":"26","author":"G Palladini","year":"2017","unstructured":"Palladini G, Jaccard A, Milani P, Lavergne D, Foli A et al (2017) Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clin Chem Lab Med 26:1734\u20131743","journal-title":"Clin Chem Lab Med"},{"key":"2958_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2369-9-11","volume":"9","author":"CA Hutchison","year":"2008","unstructured":"Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M et al (2008) Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 9:11","journal-title":"BMC Nephrol"},{"key":"2958_CR27","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","volume":"107","author":"G Palladini","year":"2003","unstructured":"Palladini G, Campana C, Klersy C, Balduini A, Vadacca G et al (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440\u20132445. https:\/\/doi.org\/10.1161\/01.CIR.0000068314.02595.B2 (Epub 2003 Apr 28)","journal-title":"Circulation"},{"key":"2958_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3324\/haematol.2011.040493","volume":"96","author":"AD Wechalekar","year":"2011","unstructured":"Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN (2011) Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica 96:1079\u20131080","journal-title":"Haematologica"},{"key":"2958_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.yjmcc.2004.01.001","volume":"36","author":"KK Ma","year":"2004","unstructured":"Ma KK, Ogawa T, de Bold AJ (2004) Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 36:505\u2013513","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"2958_CR30","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B et al (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 107(9):4188\u20134193","journal-title":"Proc Natl Acad Sci USA"},{"key":"2958_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/asheducation.V2012.1.595.3798563","volume":"2012","author":"G Merlini","year":"2012","unstructured":"Merlini G, Palladini G (2012) Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematol Am Soc Hematol Educ Program 2012:595\u2013603","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2958_CR32","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2017-06-790469","volume":"130","author":"G Palladini","year":"2017","unstructured":"Palladini G, Basset M, Milani P, Varettoni M et al (2017) Biomarker- based screening of organ dysfunction in patients with MGUS allows early diagnosis of AL amyloidosis. Blood 130:1760","journal-title":"Blood"},{"key":"2958_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol 79:319\u2013328","journal-title":"Am J Hematol"},{"key":"2958_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ajh.23141","volume":"87","author":"G Palladini","year":"2012","unstructured":"Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, Obici L, Perlini S, Moratti R, Merlini G (2012) Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 87:465\u2013471","journal-title":"Am J Hematol"},{"key":"2958_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2459\/JCM.0000000000000349","volume":"17","author":"F Perfetto","year":"2016","unstructured":"Perfetto F, Bergesio F, Grifoni E, Fabbri A, Ciuti G et al (2016) Different NT-proBNP circulating levels for different types of cardiac amyloidosis. J Cardiovasc Med 17:810\u2013817","journal-title":"J Cardiovasc Med"},{"key":"2958_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","volume":"15","author":"M Grandis","year":"2020","unstructured":"Grandis M, Obici L, Luigetti M, Briani C, Benedicenti F et al (2020) Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis 15:348","journal-title":"Orphanet J Rare Dis"},{"key":"2958_CR37","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751\u20133757","journal-title":"J Clin Oncol"},{"key":"2958_CR38","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA et al (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121:3420\u20133427","journal-title":"Blood"},{"key":"2958_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989\u2013995","journal-title":"J Clin Oncol"},{"key":"2958_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1200\/JCO.18.01398","volume":"37","author":"SK Kumar","year":"2019","unstructured":"Kumar SK, Gertz MA, Dispenzieri A (2019) Validation of Mayo Clinic staging system for light chain amyloidosis with high-sensitivity troponin. J Clin Oncol 37:171\u2013173","journal-title":"J Clin Oncol"},{"key":"2958_CR41","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","volume":"104","author":"T Dittrich","year":"2019","unstructured":"Dittrich T, Benner A, Kimmich C, Siepen FAD, Veelken K et al (2019) Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica 104:1451\u20131459","journal-title":"Haematologica"},{"key":"2958_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","volume":"133","author":"B Lilleness","year":"2019","unstructured":"Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V (2019) Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 133:215\u2013223","journal-title":"Blood"},{"key":"2958_CR43","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/bloodadvances.2020003782","volume":"5","author":"N Abdallah","year":"2021","unstructured":"Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P et al (2021) Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Adv 5:1029\u20133601","journal-title":"Blood Adv"},{"key":"2958_CR44","unstructured":"Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, Merlini G, Tosi P, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation (2004) Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GTMO). Haematologica 89:717\u2013741"},{"key":"2958_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/10428190701684518","volume":"49","author":"M Gertz","year":"2008","unstructured":"Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S et al (2008) Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 49:36\u201341","journal-title":"Leuk Lymphoma"},{"key":"2958_CR46","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/bmt.2012.170","volume":"48","author":"MA Gertz","year":"2013","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D et al (2013) Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transpl 48:557\u2013561","journal-title":"Bone Marrow Transpl"},{"key":"2958_CR47","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135:1357\u20131377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024438","journal-title":"Circulation"},{"issue":"3","key":"2958_CR48","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11739-020-02474-1","volume":"16","author":"S Bartolini","year":"2021","unstructured":"Bartolini S, Baldasseroni S, Fattirolli F, Silverii MV, Piccioli L, Perfettop F, Marchionni N, Di Mario C, Martone R, Taborchi G, Morini S, Vignini E, Cappelli F (2021) Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients. Intern Emerg Med 16(3):653\u2013660. https:\/\/doi.org\/10.1007\/s11739-020-02474-1 (Epub 2020 Sep 12)","journal-title":"Intern Emerg Med"},{"issue":"9","key":"2958_CR49","doi-asserted-by":"publisher","first-page":"688","DOI":"10.2459\/JCM.0000000000001036","volume":"21","author":"M Gospodinova","year":"2020","unstructured":"Gospodinova M, Sarafov S, Chamova T, Kirov A, Todorov T, Nakov R, Todorova A, Denchev S, Tournev I (2020) Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation. J Cardiovasc Med (Hagerstown) 21(9):688\u2013695. https:\/\/doi.org\/10.2459\/JCM.0000000000001036","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2958_CR50","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68:1014\u20131020","journal-title":"J Am Coll Cardiol"},{"key":"2958_CR51","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2017","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ et al (2017) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799\u20132806","journal-title":"Eur Heart J"},{"key":"2958_CR52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cjca.2019.12.020","volume":"36","author":"F Cappelli","year":"2020","unstructured":"Cappelli F, Martone R, Gabriele M, Taborchi G, Morini S et al (2020) Biomarkers and prediction of prognosis in transthyretin-related cardiac amyloidosis: direct comparison of two staging systems. Can J Cardiol 36:424\u2013431","journal-title":"Can J Cardiol"},{"key":"2958_CR53","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","volume":"2","author":"RK Cheng","year":"2020","unstructured":"Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los SJ et al (2020) Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol 2:414\u2013424","journal-title":"JACC CardioOncol"},{"key":"2958_CR54","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541\u20134549","journal-title":"J Clin Oncol"},{"key":"2958_CR55","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","volume":"130","author":"T Dittrich","year":"2017","unstructured":"Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A et al (2017) AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood 130:632\u2013642","journal-title":"Blood"},{"key":"2958_CR56","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/leu.2017.286","volume":"32","author":"S Sidana","year":"2018","unstructured":"Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK et al (2018) Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia 32:729\u2013735","journal-title":"Leukemia"},{"key":"2958_CR57","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Merlini G (2017) Patients with light chain (AL) amyloidosis and low free light chain burden have distinct clinical features and outcome. Blood 130:625\u2013631","journal-title":"Blood"},{"issue":"1","key":"2958_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","volume":"28","author":"G Palladini","year":"2021","unstructured":"Palladini G, Sch\u00f6nland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, Milani P, Ando Y, Westermark P, Dispenzieri A, Merlini G (2021) Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid 28(1):1\u20132. https:\/\/doi.org\/10.1080\/13506129.2020.1868810 (Epub 2021 Jan 7)","journal-title":"Amyloid"},{"key":"2958_CR59","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjh.16198","volume":"188","author":"B Lilleness","year":"2020","unstructured":"Lilleness B, Doros G, Ruberg FL, Sanchorawala V (2020) Establishment of brain natriuretic peptide-based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. Br J Haematol 188:424\u2013427127","journal-title":"Br J Haematol"},{"key":"2958_CR60","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","volume":"136","author":"G Palladini","year":"2020","unstructured":"Palladini G, Milani P, Merlini G (2020) Management of AL amyloidosis in 2020. Blood 136:2620\u20132627. https:\/\/doi.org\/10.1182\/blood.2020006913","journal-title":"Blood"},{"key":"2958_CR61","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","volume":"116","author":"G Palladini","year":"2016","unstructured":"Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P et al (2016) The combination of high-sensitivity cardiactroponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide typeB (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116:3426\u20133431","journal-title":"Blood"},{"key":"2958_CR62","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","volume":"107","author":"G Palladini","year":"2006","unstructured":"Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854\u20133858","journal-title":"Blood"},{"key":"2958_CR63","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1002\/ajh.23936","volume":"90","author":"E Kastritis","year":"2015","unstructured":"Kastritis E, Roussou M, Gavriatopoulou M, Migkou M, Kalapanida D et al (2015) Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol 90:E60\u2013E65","journal-title":"Am J Hematol"},{"key":"2958_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","volume":"136","author":"G Palladini","year":"2020","unstructured":"Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC et al (2020) Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 136:71\u201380","journal-title":"Blood"},{"key":"2958_CR65","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","volume":"116","author":"G Palladini","year":"2010","unstructured":"Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P et al (2010) The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116:3426\u20133430","journal-title":"Blood"},{"key":"2958_CR66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ajh.23898","volume":"90","author":"GP Kaufman","year":"2015","unstructured":"Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK et al (2015) Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol 90:181\u2013186","journal-title":"Am J Hematol"},{"key":"2958_CR67","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ajh.21822","volume":"85","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ et al (2010) Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 85:757\u2013759","journal-title":"Am J Hematol"},{"key":"2958_CR68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","volume":"10","author":"S Sidana","year":"2020","unstructured":"Sidana S, Milani P, Binder M, Basset M, Tandon N et al (2020) A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J 10:41. https:\/\/doi.org\/10.1038\/s41408-020-0306-5","journal-title":"Blood Cancer J"},{"issue":"10","key":"2958_CR69","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2459\/JCM.0000000000001192","volume":"22","author":"G Ciliberti","year":"2021","unstructured":"Ciliberti G, Urbinati A, Barbarossa A, Stronati G, Silenzi M, Principi S, Falanga U, Capucci A, Casella M, Dello Russo A, Guerra F (2021) Compassionate drug use for patients with transthyretin amyloid cardiomyopathy. J Cardiovasc Med (Hagerstown) 22(10):792\u2013794. https:\/\/doi.org\/10.2459\/JCM.0000000000001192","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2958_CR70","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","volume":"40","author":"M Emdin","year":"2019","unstructured":"Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferovic PM, Barison A, Castiglione V, Vergano G, Giannoni A et al (2019) Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 40:3699\u20133706","journal-title":"Eur Heart J"},{"key":"2958_CR71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/13506129.2010.483118","volume":"17","author":"J Buxbaum","year":"2010","unstructured":"Buxbaum J, Anan I, Suhr O (2010) Serum transthyretin levels in Swedish TTR V30M carriers. Amyloid 17:83\u201385. https:\/\/doi.org\/10.3109\/13506129.2010.483118","journal-title":"Amyloid"},{"key":"2958_CR72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00000441-198501000-00003","volume":"289","author":"M Skinner","year":"1985","unstructured":"Skinner M, Connors LH, Rubinow A, Libbey C, Sipe JD et al (1985) Lowered prealbumin levels in patients with familial amyloid polyneuropathy(FAP) and their non-affected but at risk relatives. Am J Med Sci 289:17\u201321","journal-title":"Am J Med Sci"},{"key":"2958_CR73","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/0960-8966(96)88826-2","volume":"6","author":"T Coelho","year":"1996","unstructured":"Coelho T, Chor\u00e3o R, Sousa A, Alves A, Torres MF et al (1996) Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. J Neuromusc Disord 6:S20","journal-title":"J Neuromusc Disord"},{"key":"2958_CR74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ et al (2019) Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 74:285\u2013295","journal-title":"J Am Coll Cardiol"},{"key":"2958_CR75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"issue":"1","key":"2958_CR76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"key":"2958_CR77","doi-asserted-by":"publisher","unstructured":"Law S, Petrie A, Chacko L, Cohen OC, Ravichandran S, Gilbertson JA, Rowczenio D, Wechalekar AD, Martinez-Naharro A, Lachmann HJ, Whelan CJ, Hutt DF, Hawkins PN, Fontana M, Gillmore JD (2021) Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart. https:\/\/doi.org\/10.1136\/heartjnl-2021-319063(Epub ahead of print)","DOI":"10.1136\/heartjnl-2021-319063"},{"key":"2958_CR78","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","volume":"131","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E et al (2018) Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood 131:1568\u20131575","journal-title":"Blood"},{"key":"2958_CR79","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ajh.24001","volume":"90","author":"A Dispenzieri","year":"2015","unstructured":"Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ et al (2015) Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol 90:524\u2013528","journal-title":"Am J Hematol"},{"key":"2958_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaccao.2020.01.006","volume":"2","author":"KW Zhang","year":"2020","unstructured":"Zhang KW, Miao J, Mitchell JD, Alvarez-Cardona J, Tomasek K et al (2020) Plasma hepatocyte growth factor for diagnosis and prognosis in light chain and transthyretin cardiac amyloidosis. JACC Cardio Oncol 2:56\u201366","journal-title":"JACC Cardio Oncol"},{"key":"2958_CR81","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3109\/13506129.2011.627069","volume":"18","author":"G Palladini","year":"2011","unstructured":"Palladini G, Barassi A, Perlini S, Milani P, Foli A et al (2011) Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid 18:216\u2013221","journal-title":"Amyloid"},{"key":"2958_CR82","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","volume":"128","author":"E Kastritis","year":"2016","unstructured":"Kastritis E, Papassotiriou I, Terpos E, Roussou M, Gavriatopoulou M et al (2016) Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood 128:405\u2013409","journal-title":"Blood"},{"key":"2958_CR83","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/13506129.2011.588977","volume":"18","author":"L Weng","year":"2011","unstructured":"Weng L, Spencer BH, SoohHoo PT, Connors LH, O\u2019Hara CJ, Seldin DC (2011) Dysregulation of miRNAs in AL amyloidosis. Amyloid 18:128\u2013135","journal-title":"Amyloid"},{"key":"2958_CR84","unstructured":"Fishov H, Muchtar E, Salmon-Divon M, Dispenzieri A, Shpilberg O, Hershkovitz-Rokah O (2020) The role of MicroRNA in the pathogenesis of AL amyloidosis. In: XVII International symposium on amyloidosis Tarragona Spain 14th\u201318th September 2020, PM026, pp 105\u2013106"},{"issue":"10","key":"2958_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204235","volume":"13","author":"AA Derda","year":"2018","unstructured":"Derda AA, Pfanne A, B\u00e4r C, Schimmel K, Kennel PJ et al (2018) Blood-based microRNA profiling in patients with cardiac amyloidosis. PLoS ONE 13(10):e0204235. https:\/\/doi.org\/10.1371\/journal.pone.0204235","journal-title":"PLoS ONE"},{"key":"2958_CR86","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fnmol.2020.00102","volume":"13","author":"GL Vita","year":"2020","unstructured":"Vita GL, Aguennouz M, Polito F, Oteri R, Russo M, Gentile L et al (2020) Circulating microRNAs profile in patients with transthyretin variant amyloidosis frontiers in molecular. Neuroscience 13:102\u2013111. https:\/\/doi.org\/10.3389\/fnmol.2020.00102","journal-title":"Neuroscience"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-02958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-022-02958-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-02958-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T05:52:38Z","timestamp":1668232358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-022-02958-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1007\/s11739-022-02958-2","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript is not a clinical study, but an up to date review aimed to summarize the current clinical use of circulating biomarkers for the management of cardiac amyloidosis, collecting and discussing the current literature on this topic.  Thus, the authors have not directly involved  humans and\/or animals in the drafting of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement and Informed consent"}}]}}